Business
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable
About this update from Sellas Life Sciences Group, Inc.
[{"type":"text","content":"Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17 Patients in Q4 2022 NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today the completion of enrollment in the Phase 1/2 clinical trial of the Company’s lead asset, galinpepimut-S (GPS), in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer. The endpoints of the study include safety, overall response rate, progression-free survival, overall survival and immune response correlates. The clinical trial is being conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J. USA (known as MSD outside of the United States and Canada). The total expected enrolled and evaluable number of patients is 17. Data from 15 patients will be examined by mid-2022, with final data analysis for all evaluable patients expected by the end of 2022. SELLAS and Merck will jointly perform applicable analyses of the study, including survival, immune-biological and any other analyses of interest, to assess the safety and efficacy profile of the combination of GPS and pembrolizumab in this difficult-to-treat metastatic ovarian cancer indication. “Completion of enrollment is an important milestone as we work diligently to evaluate a much-needed therapeutic treatment option for second or third line relapsed or refractory metastatic ovarian cancer patients,” said Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. “Our ability to complete enrollment timely, especially given the challenges related to COVID, is a tremendous accomplishment. We greatly appreciate the level of commitment Merck has given to this collaboration and are deeply grateful to all patients and their families, as well as investigators and study staff involved.” About Ovarian CancerOvarian cancer is one of the most common gynecologic malignancies and the fifth most frequent cause of...